These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 19474068)

  • 1. A multicentre cohort experience with double-boosted protease inhibitors.
    Stebbing J; Scourfield A; Koh G; Taylor C; Taylor S; Wilkins E; Gazzard B; Nelson M; Jones R
    J Antimicrob Chemother; 2009 Aug; 64(2):434-5. PubMed ID: 19474068
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting.
    Siripassorn K; Manosuthi W; Chottanapund S; Pakdee A; Sabaitae S; Prasithsirikul W; Tunthanathip P; Ruxrungtham K;
    AIDS Res Hum Retroviruses; 2010 Feb; 26(2):139-48. PubMed ID: 20156097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy.
    ;
    HIV Med; 2000 Mar; 1(2):76-101. PubMed ID: 11737331
    [No Abstract]   [Full Text] [Related]  

  • 4. Scientific considerations for pharmacoenhancers in antiretroviral therapy.
    Arya V; Robertson SM; Struble KA; Murray JS
    J Clin Pharmacol; 2012 Aug; 52(8):1128-33. PubMed ID: 21712496
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study.
    Giuntini R; Martinelli C; Ricci E; Vichi F; Gianelli E; Madeddu G; Abeli C; Palvarini L; Penco G; Marconi P; Grosso C; Pellicano G; Bonfanti P; Quirino T
    HIV Med; 2010 Jan; 11(1):40-5. PubMed ID: 19686438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Status of anti-HIV-1 chemotherapy in Japan.
    Oishi T; Sugiura W; Matsuda M; Abumi H; Okano A; Yamada K; Koike M; Taki M; Ishikawa M; Miura T; Fukutake K; Gouchi K; Ajisawa A; Iwamoto A; Hanabusa H; Mimaya J; Takamatsu J; Takata N; Kakishita E; Higasa S; Yoshioka A; Kashiwagi S; Shirahata A; Nagai Y
    Jpn J Infect Dis; 1999 Apr; 52(2):51-2. PubMed ID: 10817968
    [No Abstract]   [Full Text] [Related]  

  • 7. Considerations on the effectiveness of nevirapine in protease inhibitor-based regimen simplification.
    Martínez E; Gatell JM
    AIDS; 2007 Aug; 21(13):1829-30. PubMed ID: 17690588
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
    Martínez E; Larrousse M; Llibre JM; Gutiérrez F; Saumoy M; Antela A; Knobel H; Murillas J; Berenguer J; Pich J; Pérez I; Gatell JM;
    AIDS; 2010 Jul; 24(11):1697-707. PubMed ID: 20467288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UK HIV drug resistance database: background and recent outputs.
    Dunn D; Pillay D
    J HIV Ther; 2007 Dec; 12(4):97-8. PubMed ID: 18578092
    [No Abstract]   [Full Text] [Related]  

  • 11. Switch study of nevirapine.
    AIDS Patient Care STDS; 2000 Dec; 14(12):672. PubMed ID: 11187109
    [No Abstract]   [Full Text] [Related]  

  • 12. Superior virological response to boosted protease inhibitor-based highly active antiretroviral therapy in an observational treatment programme.
    Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS
    HIV Med; 2007 Mar; 8(2):80-5. PubMed ID: 17352763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superior virological efficacy of ritonavir-boosted protease inhibitor regimens compared to single protease inhibitor therapy.
    Lichterfeld M; Wöhrmann A; Schmeisser N; Fätkenheuer G; Salzberger B; Wyen C; Schmitz K; Sauerbruch T; Rockstroh JK
    Eur J Med Res; 2003 Feb; 8(2):56-60. PubMed ID: 12626282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication.
    Parienti JJ; Ragland K; Lucht F; de la Blanchardière A; Dargère S; Yazdanpanah Y; Dutheil JJ; Perré P; Verdon R; Bangsberg DR;
    Clin Infect Dis; 2010 Apr; 50(8):1192-7. PubMed ID: 20210643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virological suppression achieved with suboptimal adherence levels among South African children receiving boosted protease inhibitor-based antiretroviral therapy.
    Müller AD; Myer L; Jaspan H
    Clin Infect Dis; 2009 Jan; 48(1):e3-5. PubMed ID: 19025495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial.
    Miró JM; Manzardo C; Pich J; Domingo P; Ferrer E; Arribas JR; Ribera E; Arrizabalaga J; Loncá M; Cruceta A; de Lazzari E; Fuster M; Podzamczer D; Plana M; Gatell JM;
    AIDS Res Hum Retroviruses; 2010 Jul; 26(7):747-57. PubMed ID: 20624069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.
    Lima VD; Gill VS; Yip B; Hogg RS; Montaner JS; Harrigan PR
    J Infect Dis; 2008 Jul; 198(1):51-8. PubMed ID: 18498238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral choices under the DHHS guidelines.
    Boyle BA
    AIDS Read; 2004 Feb; 14(2):71-4, 77. PubMed ID: 14997862
    [No Abstract]   [Full Text] [Related]  

  • 19. Virological treatment failure of highly active antiretroviral therapy in an unselected cohort of HIV-infected patients.
    Bonfanti P; Capetti A; Di Mattei P; Niero F; Rizzardini G
    AIDS; 1998 Jun; 12(9):1111. PubMed ID: 9662213
    [No Abstract]   [Full Text] [Related]  

  • 20. Response of severe HIV-associated thrombocytopenia to highly active antiretroviral therapy including protease inhibitors.
    Carbonara S; Fiorentino G; Serio G; Maggi P; Ingravallo G; Monno L; Bruno F; Coppola S; Pastore G; Angarano G
    J Infect; 2001 May; 42(4):251-6. PubMed ID: 11545567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.